Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson & ...

Please provide your email address to receive an email when new articles are posted on . Low body surface area psoriasis in sensitive or highly visible areas is often prescribed only topical ...

"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...

HORSHAM, Pa. - The U.S. Food and Drug Administration has approved Johnson & Johnson’s (NYSE:JNJ) Tremfya (guselkumab) for treating children six years and older who weigh at least 40 kg with moderate ...